BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

829.07M

Vuru Grade

31.00/100

Current Price

$11.32
+0.10 (+0.89%)

Stability Price

$0.21
Overvalued by 98.10%

Company Metrics

  • P/E 0
  • P/S 19.87
  • P/B 10.79
  • EPS -0.43
  • Cash ROIC -229.93%
  • Cash Ratio 1.26
  • Dividend 0 / N/A %
  • Avg. Vol. 1.06M
  • Shares 73.24M
  • Market Cap. 829.07M

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Investors' Radars Failed to Catch BioCryst Pharmaceuticals (BCRX), Has Yours?
Zacks.com - 2 hours ago
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is BioCryst Pharmaceuticals, Inc. (BCRX - Snapshot Report). This med-drugs stock has actually seen loss estimates narrowing over the past month ...
Momentum Stock in Focus: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Enterprise Leader - Sep 1, 2015
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given a top momentum style rating by Zacks Research. This rating is an indicator of when a stock might be favorable to enter a position to take advantage of the equity movement in either an upward ...
BioCryst Pharmaceuticals, Inc. Analyst Rating Update - Insider Trading Report
Brokerages Set BioCryst Pharmaceuticals Target Price at $16.71 (NASDAQ:BCRX) - Financial Wisdom Works
Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's Strong On High ...
TheStreet.com - Aug 31, 2015
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
Morning Top Movers: Zoetis Inc. (ZTS), BioCryst Pharmaceuticals, Inc. (BCRX ... - WallStreet Scope
Fear These Three Biotech Stocks: Amicus Therapeutics, Inc. (NASDAQ:FOLD ...
Wall Street Point - 2 hours ago
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) closed at $11.22 with a decrease of 3.61%. The $852.51M company on August 7, 2015 announced financial results for the second quarter ended June 30, 2015.
Large Outflow of Money Witnessed in BioCryst Pharmaceuticals, Inc.
Money Flow Index - Aug 24, 2015
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) advanced to $11.99. The price had gained 4.53% or 0.52 points intraday.
Zacks Short Term Rating on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - American Trade Journal
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Rally 2.65% - Insider Trading Report
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Analyst Rating Update
Investor Newswire - Aug 31, 2015
Wall Street analysts polled by Zacks Research have given BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a rating of 1.29 on a consensus basis.
BioCryst Pharmaceuticals, Inc. Short Interest Update
Insider Trading Report - Aug 26, 2015
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ensharesed a drop of 4.9% or -408,587 shares in the short positions. The number dropped from 8,384,510 on July 31,2015 to 7,975,923 on August 14,2015.
Biotech Stocks to bet on: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ... - Wall Street Point
BioCryst Pharmaceuticals Receives Average Rating of "Buy" from Analysts ... - Dakota Financial News
Durham's BioCryst cuts $45 million deal with Australian firm
Triangle Business Journal - Jun 17, 2015
Durham-based BioCryst Pharmaceuticals, Inc., (Nasdaq: BCRX) licensed its recently approved flu treatment Rapivap in a deal that could bring the company $45 million plus sales royalties.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has licensed RAPIVAB (peramivir ... - Inside Trade
BioCryst Pharma licenses flu med to CSL Limited (BCRX) - Seeking Alpha
BioCryst Pharmaceuticals, Inc. Price Target Update
Money Flow Index - Aug 21, 2015
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock has received a short term price target of $ 19.17 from 6 Analyst.
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Business Summary - Markets Wired
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Large Outflow of Money - American Trade Journal
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target Update
Insider Trading Report - Aug 28, 2015
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): 6 analysts have set the short term price target of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) at $19.17. The standard deviation of short term price target has been estimated at $2.86, implying that the ...